Browse studies

Find your next paid study

4 recruiting studies matching your filters

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to near…

Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT05099172

Phase 1

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cel…

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nuvectis Pharma, Inc.NCT07315113

Phase 1

An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cel…

Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148

Phase 3

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Versus Placebo in Early Stage NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC…

Lung CancerAdjuvantPost-surgical+5 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Taiho Oncology, Inc.NCT07128199